Skip to main content
. 2018 May 23;36(22):2281–2287. doi: 10.1200/JCO.2017.77.2285

Fig A1.

Fig A1.

Kaplan-Meier curves for distant disease-free survival (DDFS). (A) Comparison of DDFS in all patients. Hazard ratio (HR), 0.554 (95% CI, 0.329 to 0.933; P = .024). (B) Comparison of the effects of pathologic complete response (pCR) on the DDFS. The HR for pCR in mutation carriers was 0.74 (95% CI, 0.27 to 1.98; P = .541); the HR for pCR in patients without mutations was 0.19 (95% CI, 0.10 to 0.34; P < .001). The interaction test showed a P value of 0.0195. (C) Comparison of DDFS relative to the treatment arm and mutation status. The HRs for bevacizumab treatment were 0.97 (95% CI, 0.36 to 2.60; P = .947) in patients with a BRCA1/2 mutation and 1.15 (95% CI, 0.81 to 1.64; P = .432) in patients without a BRCA1/2 mutation. P(interaction) = .756.